NO20003775L - FremgangsmÕte for behandling av inflammatoriske sykdommer ved anvendelse av varmesjokkproteiner - Google Patents

FremgangsmÕte for behandling av inflammatoriske sykdommer ved anvendelse av varmesjokkproteiner

Info

Publication number
NO20003775L
NO20003775L NO20003775A NO20003775A NO20003775L NO 20003775 L NO20003775 L NO 20003775L NO 20003775 A NO20003775 A NO 20003775A NO 20003775 A NO20003775 A NO 20003775A NO 20003775 L NO20003775 L NO 20003775L
Authority
NO
Norway
Prior art keywords
heat shock
inflammatory diseases
treating inflammatory
shock proteins
response
Prior art date
Application number
NO20003775A
Other languages
English (en)
Norwegian (no)
Other versions
NO20003775D0 (no
Inventor
Erwin W Gelfand
Angela Francisca Haczku
Katalin Veronika Lukacs
Original Assignee
Nat Jewish Med & Res Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Jewish Med & Res Center filed Critical Nat Jewish Med & Res Center
Publication of NO20003775D0 publication Critical patent/NO20003775D0/no
Publication of NO20003775L publication Critical patent/NO20003775L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20003775A 1998-01-23 2000-07-21 FremgangsmÕte for behandling av inflammatoriske sykdommer ved anvendelse av varmesjokkproteiner NO20003775L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1233098A 1998-01-23 1998-01-23
PCT/US1999/001421 WO1999037319A1 (fr) 1998-01-23 1999-01-22 Methode de traitement des maladies inflammatoires utilisant des proteines du stress

Publications (2)

Publication Number Publication Date
NO20003775D0 NO20003775D0 (no) 2000-07-21
NO20003775L true NO20003775L (no) 2000-09-22

Family

ID=21754459

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003775A NO20003775L (no) 1998-01-23 2000-07-21 FremgangsmÕte for behandling av inflammatoriske sykdommer ved anvendelse av varmesjokkproteiner

Country Status (16)

Country Link
US (2) US20020006410A1 (fr)
EP (1) EP1049483A1 (fr)
JP (1) JP2002509074A (fr)
KR (1) KR20010040389A (fr)
CN (1) CN1324243A (fr)
AU (1) AU2337499A (fr)
BR (1) BR9907228A (fr)
CA (1) CA2318263A1 (fr)
CZ (1) CZ20002669A3 (fr)
HU (1) HUP0100241A2 (fr)
IL (1) IL137404A0 (fr)
NO (1) NO20003775L (fr)
PL (1) PL342166A1 (fr)
TR (1) TR200002973T2 (fr)
WO (1) WO1999037319A1 (fr)
ZA (1) ZA99499B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7992572B2 (en) * 1998-06-10 2011-08-09 Asthmatx, Inc. Methods of evaluating individuals having reversible obstructive pulmonary disease
AU3239400A (en) * 1999-02-22 2000-09-04 University Of Iowa Research Foundation, The Method for inhibiting inflammatory responses
WO2001022816A1 (fr) * 1999-09-30 2001-04-05 National Jewish Medical And Research Center MODULATION DES LEUCOCYTES T ηδ DESTINEE A REGULER L'HYPERSENSIBILITE DES BRONCHES
US6737398B1 (en) 1999-09-30 2004-05-18 National Jewish Medical And Research Center Modulation of γδ T cells to regulate airway hyperresponsiveness
US7235649B2 (en) * 2000-03-24 2007-06-26 Duke University Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same
GB0028122D0 (en) * 2000-11-17 2001-01-03 St Georges Entpr Ltd Method
AUPR381601A0 (en) * 2001-03-19 2001-04-12 Monash University Method of treating respiratory conditions
AU2002327804B2 (en) * 2001-10-01 2008-09-11 Duke University Three dimensional structure of crystalline GRP94 binding domain, and its methods of use
JP4632664B2 (ja) * 2002-02-13 2011-02-16 デューク ユニバーシティ 非ペプチド結合ストレス応答性ポリペプチドによる免疫応答の調節
US20100111927A1 (en) * 2002-08-23 2010-05-06 Sunyoung Kim Compositions Comprising Actinidia and Methods of Use Thereof
KR100615389B1 (ko) * 2002-08-23 2006-08-25 (주)헬릭서 다래 추출물을 함유하는 알러지성 질환 및 비알러지성염증 질환의 예방 및 개선용 건강 기능 식품
GB0226105D0 (en) * 2002-11-08 2002-12-18 St Georges S Entpr Ltd Pain relief agents
CA2626692A1 (fr) * 2005-10-20 2007-04-26 Cbio Limited Traitement de l'hypersensibilite
KR100768265B1 (ko) * 2005-11-10 2007-10-17 한국화학연구원 혈액내 순환시간을 향상시키기 위한 헤파린이 수식된리포솜 및 이의 제조방법
ES2385735T3 (es) 2008-06-26 2012-07-31 Orphazyme Aps Uso de Hsp70 como regulador de la actividad enzimática
WO2010086418A1 (fr) * 2009-01-29 2010-08-05 Alfa Biogene International B.V. Produit alimentaire fonctionnel comprenant une protéine de choc thermique ou un hydrolysat de celle-ci
EP2397074B1 (fr) * 2010-06-19 2012-10-24 M Stenqvist AB Système et support lisible par ordinateur stockant un programme pour déterminer la pression transpulmonaire chez un patient connecté à un appareil respiratoire
RU2013125923A (ru) 2010-11-30 2015-01-10 Орфазиме Апс СПОСОБЫ УВЕЛИЧЕНИЯ ВНУТРИКЛЕТОЧНОЙ АКТИВНОСТИ Hsp70
WO2012097255A2 (fr) * 2011-01-14 2012-07-19 Scott & White Healthcare Effet thérapeutique de protéines de choc thermique utilisées pour la prévention de l'agrégation de l'amyline dans le diabète sucré de type 2
WO2012154967A1 (fr) 2011-05-12 2012-11-15 Proteostasis Therapeutics, Inc. Régulateurs de la protéostasie
WO2012174549A2 (fr) * 2011-06-16 2012-12-20 Children's Hospital Medical Center Blocage de production d'éosinophiles par des récepteurs de type toll
US10034915B2 (en) 2011-06-23 2018-07-31 The Board Of Trustees Of The Leland Stanford Junior University Small heat shock proteins and active fragments thereof as a therapy for inflammation and ischemia
EP2806875B1 (fr) 2012-01-25 2017-07-19 Proteostasis Therapeutics, Inc. Composés permettant de moduler l'activité de protéasome
DK3193840T3 (da) 2014-09-15 2021-08-16 Orphazyme As Arimoclomol-formulering
EP3402572B1 (fr) 2016-01-13 2022-03-16 Children's Hospital Medical Center Compositions et méthodes de traitement d'états inflammatoires allergiques
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
DK3782624T3 (da) 2016-04-29 2025-12-15 Zevra Denmark As Arimoclomol til behandling af glucocerebrosidase-associerede lidelser
CN106243203B (zh) * 2016-08-04 2019-12-10 上海市农业科学院 一种草菇热激蛋白VvHSP70及其应用
CN106220718B (zh) * 2016-08-04 2019-12-10 上海市农业科学院 一种草菇热激蛋白VvHSP60及其应用
US11859250B1 (en) 2018-02-23 2024-01-02 Children's Hospital Medical Center Methods for treating eosinophilic esophagitis
EP3781588B1 (fr) 2018-04-20 2024-10-30 Children's Hospital Medical Center Biomarqueur sanguin pour troubles gastro-intestinaux éosinophiliques
CR20200652A (es) 2018-06-27 2021-04-28 Proteostasis Therapeutics Inc Compuestos que aumentan la actividad del proteosoma
JP7551087B2 (ja) 2018-06-27 2024-09-17 キネタ， インコーポレイテッド プロテアソーム活性増強化合物
US12297501B2 (en) 2019-02-25 2025-05-13 Children's Hospital Medical Center Methods for diagnosing and treating eosinophilic gastritis
EP4247792A1 (fr) 2020-11-19 2023-09-27 Zevra Denmark A/S Procédés de préparation de citrate d'arimoclomol et intermédiaires associés
CN114046596B (zh) * 2021-11-17 2022-09-23 重庆大学 基于trp生化指标检测的室内空气质量控制系统及方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5348945A (en) * 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
ATE154759T1 (de) * 1990-11-08 1997-07-15 Univ London Mycobacterium als adjuvans für antigene
GB9211736D0 (en) * 1992-06-03 1992-07-15 Univ Cardiff Allergic treatment
AU736318B2 (en) * 1996-11-26 2001-07-26 Nventa Biopharmaceuticals Corporation Immune responses using compositions containing stress proteins

Also Published As

Publication number Publication date
EP1049483A1 (fr) 2000-11-08
JP2002509074A (ja) 2002-03-26
PL342166A1 (en) 2001-05-21
US20070179087A1 (en) 2007-08-02
ZA99499B (en) 1999-07-22
CN1324243A (zh) 2001-11-28
WO1999037319A1 (fr) 1999-07-29
TR200002973T2 (tr) 2001-02-21
NO20003775D0 (no) 2000-07-21
KR20010040389A (ko) 2001-05-15
CA2318263A1 (fr) 1999-07-29
AU2337499A (en) 1999-08-09
BR9907228A (pt) 2000-10-24
IL137404A0 (en) 2001-07-24
HUP0100241A2 (hu) 2001-06-28
US20020006410A1 (en) 2002-01-17
CZ20002669A3 (cs) 2001-11-14

Similar Documents

Publication Publication Date Title
NO20003775L (no) FremgangsmÕte for behandling av inflammatoriske sykdommer ved anvendelse av varmesjokkproteiner
NO991784D0 (no) Purin-L-nukleosider, analoger og anvendelser derav
ATE228373T1 (de) Unterdrückung von autoimmunkrankheiten durch antigene in wartestellung
NL194940B (nl) Virusstam en vaccin ter voorkoming van varkensreproductie- en -respiratiesyndroom.
EA199700413A1 (ru) Композиция, содержащая вакцину и конъюгат антигена и полисахарида, адсорбированные на фосфате алюминия
DE69534992D1 (de) Mutierendes enterotoxin als nichttoxisches orales adjuvans
NO832630L (no) Trifenylimidazolyloxyalkansyrer og deres derivater, deres fremstilling og deres anvendelse i preparater
DE3854741D1 (de) Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen.
WO1996012794A3 (fr) Cellules pancreatiques porcines isolees pour le traitement de troubles caracterises par une activite insuffisante de l'insuline
FI971732L (fi) Rokote ja antitoksiini C. difficilen aiheuttaman taudin hoitamiseksi ja estämiseksi
NO931372D0 (no) Behandling av autoimmunsykdommer ved oral administrering av autoantigener
IT1229484B (it) Virus ricombinante delle malattie esantematiche dei vertebrati.
DK1733730T3 (da) Immunmodulerende oligosaccharider
BR9907995A (pt) Métodos imunológicos para modular miostatina em sujeitos vertebrados
BR9506819A (pt) Derivados de ácido micofenólico substituídos na posiçao 5
WO1996013512A3 (fr) Nucleosides de l-ribofuranosyle
DK1009413T3 (da) Anvendelse af immunstimulerende oligonukleotider til forebyggelse eller behandling af astma
NO963508L (no) Urease-basert vaksine og behandling av Helicobacter-infeksjon
ES2192839T3 (es) Timosina beta 4 oxidada.
NO881515L (no) Pulmonar surfaktant.
NZ505834A (en) Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use
EP0593290A3 (fr) Proteine antigènique du noyau du virus de l'hépatite C, et méthode diagnostiquée et nécessaire.
NO964200L (no) Behandling av autoimmun sykdom ved anvendelse av oral tolerisering og/eller Th2-forsterkende cytokiner
NO964199L (no) Behandling av autoimmun sykdom ved anvendelse av oral tolerisering og/eller type I interferon
BG93298A (bg) Имуностимулиращи 6-арил-5,6-дихидроимидазо(2,1-в)тиазолови производни

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application